IRIS
LAUDICELLA, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.567
NA - Nord America 3.075
AS - Asia 2.359
SA - Sud America 746
AF - Africa 81
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.971
RU - Federazione Russa 2.643
SG - Singapore 1.039
BR - Brasile 616
CN - Cina 495
IE - Irlanda 422
IT - Italia 402
SE - Svezia 390
HK - Hong Kong 296
DE - Germania 170
VN - Vietnam 149
FR - Francia 124
IN - India 101
GB - Regno Unito 87
PL - Polonia 86
FI - Finlandia 51
AR - Argentina 50
CA - Canada 49
MX - Messico 37
NL - Olanda 33
AT - Austria 32
BD - Bangladesh 31
JP - Giappone 31
ZA - Sudafrica 30
TR - Turchia 28
ID - Indonesia 26
IQ - Iraq 26
BE - Belgio 24
ES - Italia 23
LT - Lituania 23
VE - Venezuela 17
PK - Pakistan 16
UZ - Uzbekistan 15
EC - Ecuador 14
TN - Tunisia 14
MA - Marocco 13
PE - Perù 13
AE - Emirati Arabi Uniti 11
AZ - Azerbaigian 11
CO - Colombia 11
IR - Iran 11
PH - Filippine 11
UA - Ucraina 10
IL - Israele 9
PY - Paraguay 9
CL - Cile 8
CZ - Repubblica Ceca 7
SA - Arabia Saudita 7
GE - Georgia 6
MY - Malesia 6
KE - Kenya 5
KW - Kuwait 5
PT - Portogallo 5
UY - Uruguay 5
CH - Svizzera 4
EG - Egitto 4
JO - Giordania 4
NO - Norvegia 4
NP - Nepal 4
PA - Panama 4
AL - Albania 3
BG - Bulgaria 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
JM - Giamaica 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
OM - Oman 3
PR - Porto Rico 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AU - Australia 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
DZ - Algeria 2
LU - Lussemburgo 2
NG - Nigeria 2
RO - Romania 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
CM - Camerun 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
Totale 10.825
Salva come PNG Salva come JPEG
Città #
Moscow 803
Ashburn 575
Singapore 533
Dublin 420
Chandler 413
Hong Kong 295
Nyköping 288
Dallas 262
San Jose 196
Beijing 150
The Dalles 123
Messina 113
Los Angeles 112
Warsaw 78
Princeton 74
Munich 70
Medford 61
São Paulo 58
Ho Chi Minh City 53
Lauterbourg 45
New York 40
Bremen 37
Des Moines 36
Redondo Beach 34
Buffalo 32
Santa Clara 32
Rome 29
Hyderabad 28
Hanoi 27
Frankfurt am Main 26
Helsinki 26
Orem 25
Brussels 24
Nuremberg 23
Montreal 22
Palermo 22
Stockholm 20
Tianjin 20
Tokyo 20
Jacksonville 19
Johannesburg 19
Atlanta 17
Dearborn 17
Mumbai 17
Seattle 17
Turku 17
Vienna 17
London 16
Amsterdam 15
Denver 15
Jakarta 15
Porto Alegre 14
Boston 13
Brasília 13
Chennai 13
Council Bluffs 13
Guangzhou 13
Jinan 13
Milan 13
Rio de Janeiro 13
Tashkent 13
Boardman 12
Brooklyn 12
Curitiba 12
Poplar 12
Ben Arous 11
Campinas 11
Mexico City 11
Ann Arbor 10
Baku 10
Chicago 10
Kameido 10
Nanjing 10
Pune 10
Belo Horizonte 9
Bexley 9
Genoa 9
Houston 9
Istanbul 9
Lima 9
Phoenix 9
Shanghai 9
Shenzhen 9
Toronto 9
Baghdad 8
Dong Ket 8
Lappeenranta 8
San Francisco 8
Ankara 7
Betim 7
Cagliari 7
Caracas 7
Chengdu 7
Dhaka 7
Guayaquil 7
Haiphong 7
Hangzhou 7
Nanchang 7
Shenyang 7
São José do Rio Preto 7
Totale 5.924
Salva come PNG Salva come JPEG
Nome #
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 210
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 199
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 198
PRRT Retreatments: Renal Function Evaluation 197
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 193
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 191
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 190
Artificial intelligence in molecular imaging: from machine to deep learning 182
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 178
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 178
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 177
18F-FACBC in prostate cancer: A systematic review and meta-analysis 177
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 171
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 171
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 168
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 168
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 167
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 166
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 164
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 161
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 157
Renal Function Evaluation in PRRT Retreatments 156
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 148
PRRT retreatments: renal function evaluation 148
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 145
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 145
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 143
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 137
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 135
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 133
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 131
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 130
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 127
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 125
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 125
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 120
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 118
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 117
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement 116
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 114
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 113
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 113
PET/MR in neuro-oncology: is it ready for prime-time? 111
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 109
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 107
Sars-cov-2 persistence: data summary up to q2 2020 104
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 103
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 102
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 101
Molecular imaging of pancreatic neoplasms 100
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 99
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 96
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 95
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature 94
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 93
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 92
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors 91
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 89
Malignant cutaneous melanoma: Updates in PET imaging 89
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics 86
[11C]Choline PET/CT in a Patient with Prostate Cancer Biochemical Recurrence Showing Two Suspicious Findings in the Breast and Liver 86
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI 86
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond 82
Prognostic insights of molecular imaging in cardiac sarcoidosis 82
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 82
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 81
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 81
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 79
A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m 77
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 76
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 76
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 75
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 74
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 74
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 73
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study 73
[18F]PSMA‑1007 PET/CT‑based radiomics may help enhance the interpretation of bone focal uptakes in hormone‑sensitive prostate cancer patients 72
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 70
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs) 66
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review 62
Correction: PSMA‑positive prostatic volume prediction with deep learning based on T2‑weighted MRI 61
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 61
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork 60
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 60
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? 59
Reply to Perera Molligoda Arachchige AS [1] 57
PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI 54
Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients 53
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? 52
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer 51
The role of PET radiomic features in prostate cancer: a systematic review 51
Unspecic bone uptakes in PSMA PET for prostate cancer: why do they matter? 51
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 49
Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review 46
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature 46
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding ­ [68Ga] Ga‑PSMA‑11 PET scans of primary prostate cancer 45
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years 40
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer 40
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 37
Artificial intelligence in molecular imaging: from machine to deep learning 36
Totale 10.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.008
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202155 0 0 0 0 0 0 0 0 0 27 17 11
2021/2022464 6 30 4 22 31 13 27 34 6 54 35 202
2022/20231.387 119 196 70 107 91 140 17 89 482 16 36 24
2023/2024369 41 39 22 33 43 50 13 31 9 32 16 40
2024/20252.168 12 59 45 75 153 64 154 317 510 184 287 308
2025/20266.262 450 366 384 424 556 1.445 682 812 851 292 0 0
Totale 11.054